NasdaqCM - Nasdaq Real Time Price USD

CervoMed Inc. (CRVO)

1.3150 -0.1150 (-8.04%)

As of 12:36:05 PM EST. Market Open.

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

GlobeNewswire 1d ago

CRVO
-8.04%
CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)

GlobeNewswire 12d ago

CRVO
-8.04%
CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026

GlobeNewswire 29d ago

CRVO
-8.04%
CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

GlobeNewswire 1mo ago

CRVO
-8.04%
CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

GlobeNewswire 1mo ago

CRVO
-8.04%
CervoMed to Participate in September Investor Conferences

GlobeNewswire 2mo ago

CRVO
-8.04%
CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

GlobeNewswire 3mo ago

CRVO
-8.04%
CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

GlobeNewswire 4mo ago

CRVO
-8.04%
CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026

GlobeNewswire 4mo ago

CRVO
-8.04%
CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

GlobeNewswire 4mo ago

CRVO
-8.04%
CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally

Stocktwits 4mo ago

CRVO
-8.04%
CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

GlobeNewswire 4mo ago

CRVO
-8.04%

Performance Overview

Return	CRVO	S&P 500 (^GSPC)
YTD	-82.28%	+9.59%
1-Year	-79.71%	+9.80%
3-Year	-85.79%	+69.90%

U.S. markets close in 3h 14m

CervoMed Inc. (CRVO)

CervoMed Reports Third Quarter 2026 Financial Results and Provides Corporate Updates

CervoMed Announces Publication of Two Peer-Reviewed Research Articles Supporting Neflamapimod as a Potential Treatment for Dementia with Lewy Bodies (DLB)

CervoMed Presents Initial Results of Phase 2a Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Showing Positive Effects on a Key Neurodegeneration Biomarker in Late-Breaking Oral Session at ISFTD 2026

CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference

CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026

CervoMed to Participate in September Investor Conferences

CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)

CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia

CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026

CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

CRVO Stock Rockets Nearly 100% On Patent Win Before Offering News Cools Rally

CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules